Work in prostate cancer cells has shown that genistein treatment significantly up-regulated 33 miRNAs whereas miR-574-3p down-regulated EGFR expression by directly binding to the 3'UTR of EGFR, thereby inhibiting the malignant biological behavior of the tumor cells [51]. The gene discussed is EGFR; the disease is neoplasm.